Showing posts with label alzheimer's disease. Show all posts
Showing posts with label alzheimer's disease. Show all posts

Wednesday, April 13, 2016

Peptides for CNS and Alzheimer's Disease Therapy

Exclusive TIDES 2016 interview with Dieter Willbold, Ph.D., Director, ICS-6 Structural Biochemistry, Forschungszentrum Jülich, Germany. Dr. Willbold gives us some exclusive insights into the topics he will be addressing onstage at the 18th annual TIDES in just 4 weeks time. Don't miss out on this record setting meeting; join over 800 global attendees over 4 days full of insights and learnings. Register for TIDES by Friday, 4/15 and save $300 - Use the code B16180BLOG.


Dr. Willbold Interview: 

What current challenges are you facing for advancing your promising peptide for Alzheimer's disease through clinical trials?

Our main focus at the moment is to finish all the necessary preclinical tox and safety tests in order to soon get permission for a clinical phase I study with our drug candidate.

One challenge for developing therapeutics like ours that target specific aggregate species, lies in the lack of suitable analytics to measure target engagement, because most methods don't differentiate between different aggregate sizes. In addition to cognitive behavioral tests, we ourselves have therefore developed novel methods to measure efficacy and target engagement .e.g. QIAD (short for quantitative determination of interference with aggregate size distribution; Brener et al., Scientific Reports 2015), which measures Abeta oligomer elimination efficiency.


What are the advantages of peptide therapeutics over small molecules, antibodies and other protein therapeutics?

Small molecules often lack specificity, and this can lead to serious side effects and autoimmune responses. On the other hand protein-based therapeutics like antibodies possess high target selectivity and are made of natural components, but they are very big and expensive molecules. They often suffer from low oral bioavailability.

Small peptides can offer the best of both worlds in some respects: They are more target specific than small molecules but easier to produce than protein based drugs. Our drug candidate is made solely from D-enantiomeric amino acid residues and has surprisingly good oral bioavailability.


Where do you see innovation happening in the peptide field over the next 5 years?

Innovation will certainly happen in the production of peptides (cost reduction) and in the formulation of peptides (increase oral bioavailability).


______________________________________________________



Reserve your seat today to attend TIDES 2016 in Long Beach, CA and hear Dr. Willbold deliver a live presentation "Efficiency and Oral Bioavailability of Abeta Oligomer Directed D-Enantiomeric Peptides Developed for Therapy of Alzheimer's Disease", where he will delve into small soluble Abeta oligomers are suspected to be the major toxic species responsible for development and progression of Alzheimer's disease (AD). We developed highly potent D-enantiomeric peptide compounds that specifically eliminate Abeta oligomers and improve cognitive performance and stop or slow down neurodegeneration of AD transgenic mice. Data on stability and oral bioavailability clearly support the superiority of D-peptides over L-peptides.





Share this article with your social network, just click below to share now!


Wednesday, September 30, 2015

Closed Systems in Biomanufacturing Offer A Variety of Benefits

A Blog by Brandy Sargent, Editor, Cell Culture Dish.com

I recently attended IBC’s Biopharmaceutical Development and Production week (BDP) and was pleased to find talks focused on single-use technologies, flexible facilities, closed systems and continuous processing. These subjects are sometimes referred to as “biomanufacturing of the future,” because they represent a change in paradigm from traditional biomanufacturing. While we have covered single-use and continuous bioprocessing extensively on Cell Culture Dish in the past, we have not dedicated much time covering the benefits and opportunities associated with closed systems. This blog will attempt to provide a high-level review of some of the topics associated with closed systems and will provide several outside resources for readers who want to explore the topic in more detail.

Traditional Biopharmaceutical Manufacturing

Traditional biopharmaceutical manufacturing has mainly consisted of fed-batch stainless steel bioreactor runs in a fixed facility with an open system. This paradigm, while serving the biopharmaceutical industry well for many years, has faced increasing pressure as single product 20,000L scale manufacturing has begun to lose ground to smaller volume, multi-product manufacturing. This shift has occurred for several reasons, some include:
  • Increases in productivity have reduced the need for very large scale manufacturing vessels and dedicated facilities.
  • Fewer blockbuster drugs with high volumes have reduced the need for large-scale dedicated facilities.
  • Single-use technologies have enabled the implementation of smaller, more flexible manufacturing.
  • Companies have begun to embrace the idea of more flexible, multi-product facilities that can easily be scaled up or down to meet changing product demand.
As a result of the changing landscape, the traditional biomanufacturing paradigm has been challenged by new models including flexible facilities, single-use systems and continuous processes that can create a more flexible and in many cases more cost effective process. Biomanufacturing of the future incorporates technologies like single-use and models like closed systems and continuous processing to move the industry forward.

Closed and Functionally Closed Systems

There have been several definitions of what makes a closed or functionally closed system in biomanufacturing. All the definitions are similar, but I like the definitions used in the BioPharm International article “Challenging the Cleanroom Paradigm for Biopharmaceutical Manufacturing of Bulk Drug Substances.” The article provides the following definitions:
  • Closed system: A process system with equipment designed and operated such that the product is not exposed to the room environment. Materials may be introduced to a closed system, but the addition must be done in such a way to avoid exposure of the product to the room environment (e.g., by 0.2 μm filtration).
  • Functionally closed system: A process system that may be routinely opened (e.g., to install a filter or make a connection), but is returned to a closed state through a sanitization or sterilization step prior to process use. It is the owner’s responsibility to define and validate the sanitization or sterilization process required to return an opened system to a functionally closed system
Benefits of a Closed or Functionally Closed System

Reduced Risk of Contamination
One of the biggest and most easily attained benefits of implementing a closed system, whether in research, pilot or large scale, is in reducing the risk of contamination by viruses or other adventitious agents. Open systems naturally provide more opportunities for contamination because the process is open to the room environment and handling by operators. There are also safety concerns associated with breeches of product containment. Operations like fluid transfer present a much higher risk in an open system where splashing and lost media can occur. A closed system, by design, provides physical barriers to reduce the risk of contamination and contain the product.

This is important because contamination can be extremely costly, not only in product loss, but also facility shut downs, cleaning and validation.

Reduced Process Time
The use of a closed system can reduce operating time. A closed system relies on less operator handling and fewer overall steps. Another time saving factor is that many of the closed system components are plug and play meaning that they come pre-assembled, designed for the job they are intended. This reduces the time it takes to set up and launch a manufacturing system significantly.

If single use technologies are employed as part of the closed system, then more time savings can be achieved. Over the course of several talks, the use of single use technologies were reported to save anywhere from a couple of days to a couple of weeks. These times savings were reported in areas including:
  • Reduced cleaning and validation time
  • Reduced set-up time
  • Reduced time to operate or oversee equipment
Examples of Benefits
One example where there is a benefit to time savings and risk reduction is in media preparation. To enable a closed system, instead of mixing and adding media, one might purchase a pre-filled media bag with a connector that is complimentary to a single use bioreactor. This creates a closed portion of the process and saves operator time of mixing media. This method also reduces risk of contamination because the media isn’t exposed to the room environment and there is reduced risk of spilling and loss of media. Aseptic transfer of large volumes of sterile media and solution can be a big challenge.

Another example was provided in a talk at BDP, titled “Processes of the Future: Single Use, Closed and Continuous for Faster, Cheaper and Safer Manufacturing,” given by Sébastien Ribault, Ph.D., Director Biotechnology/Life Science, Head of BioDevelpment Center, EMD Millipore. BDP. In Dr. Ribault’s facility, his team is operating a closed system in one of their manufacturing areas. The group needed to close the cell seeding process, so instead of banking cells in vials, they banked the cells in bags. They then thawed the bags in a water bath and seeded directly in the lab without laminar flow. This saved them time and they reported similar growth and viability to the process using cells banked in vials.

Adopting a Risk Based Approach to Manufacturing Classifications
One hot topic in the discussion around closed systems is the idea of adopting a risk-based approach when it comes to the manufacturing classifications required with closed systems. If a system is closed, or functionally closed, then a barrier already exists between the product and its environment. Therefore, is there really a need for these operations to be conducted in a Classified environment with extensive gowning and airlocks, or would it be more feasible to conduct these operations in a Controlled Non-Classified (CNC) space? The benefits associated with this type of change in classification would provide many manufacturing benefits.

At BDP, Kenneth Green, Ph.D., Head of Manufacturing Science and Technology, Shire, gave an excellent talk titled, “Pushing the Controlled Non-Classified (CNC) Envelope with the Application of Single-Use Systems for Bioprocessing.” In the talk, Dr. Green discussed the debate around whether a closed system or functionally closed system could be proved to regulators, with satisfaction, so that manufacturing could occur in a controlled non-classified environment.

If so, operating in a Controlled Non Classified (CNC) space would open up many more benefits including:
  • Enabling a truly flexible facility – by reducing the classified area requirements you could also reduce the amount of segregation in a facility and increase flexibility. There are many benefits associated with flexible manufacturing, including:
    • Smaller facilities with a simpler design that can be duplicated in multiple locations
    • Multiple products can be manufactured in the same facility or space
    • Less segregation
    • Equipment can be moved around on skids as needed to meet product demand in multiple production lines.
    • Personnel can also move more easily throughout the facility
  • Reduced operating costs include:
    • Energy savings by reducing the environmental monitoring needed and the air handling requirements
    • Removing or reducing gowning requirements reduce cost of both gown materials and provide time savings for the gowning/de-gowning processes.
The idea of employing a risk-based approach in classification requirements is a very interesting topic that could be a blog entirely on its own; however for the purposes of this article, I am only providing a high level overview. There are a number of excellent articles that cover this topic in more detail including:



Challenges to Implementation of a Closed System

Employee Training
While most of these systems are fairly easy to use, there are some major differences between stainless steel systems and single-use. Employees should be trained in maintaining the closed or functionally closed system, proper use of equipment to prevent breakage or tears and employees need to be comfortable using the tubing and connectors.

Breaking New Ground
Completely closed systems represent relatively new technologies. Ensuring all parts of your system are closed may require a good deal of ingenuity and determination particularly when using components from several suppliers. There may not be an off the shelf component that works for you and you may need to work with suppliers to create systems that work for your process.

One example of this ingenuity and determination appeared in Dr. Veena Warikoo’s talk at BDP. Dr. Warikoo, Director, Purification Development, Genzyme, gave a talk titled “Integrated and Fully Continuous Processing of Recombinant Therapeutic Proteins – From Cell Culture Media to Purified Drug Substance.” In the talk she described how Genzyme developed a closed, continuous model system for manufacturing both mAbs and non-mAbs. They had been using a continuous system upstream but needed to also close the downstream process. There wasn’t an off the shelf solution available at the time, so they partnered with GE Healthcare to develop a functionally closed periodic counter-current chromatography continuous process. She showed a picture of the system they used, then stated that GE Healthcare now offers an off the shelf version in their AKTA system.

Demonstrating to Regulators that Systems are Closed and Adopting Risk Based Approach in Classification for Closed Systems
In order to fully gain all of the benefits mentioned above, the industry must work with regulators to demonstrate that CNC manufacturing space is appropriate. BioPhorum Operations Group (BPOG) is currently working to help interpret regulatory guidance and quality expectations and prepare responses that incorporate a risk based approach.

Is a closed system right for your process? – How to navigate a transition
I was able to speak with Erika Hanley-Onken and John Shyu at Corning Life Sciences about their experiences helping customers’ transition to closed systems. They said that they like to conduct a walk through with customers to understand on a technical level the customer’s current system and how that system will transition into a new closed system. They also work with multiple vendors to create a system designed to meet customer needs and goals. Lastly, they train the company on using the new system and they will work with customers to help validate the new system. When asked what customers are most surprised by when deciding to transition they said “how long it takes, it can take weeks to months to develop the system and test it, but we provide a full quality package and we want to ensure that the customer can achieve full and consistent results.”

Goals
First it is important to consider what is the primary goal in moving to a closed system. Some examples below:
  • Designing a new facility and want to incorporate flexible manufacturing principals
  • Quality control concerns and are interested in reducing risk of contamination
  • Process improvements with desire to reduce production time or cost
Design and Implementation of a Closed System
In determining the design and implementation of your closed system it is critical to truly understand your existing process needs, strengths and weaknesses. These factors can be very helpful when working with a vendor or vendors to establish your system. It is also important to understand your current cost of goods and net present value analysis, particularly if cost is a driving factor for change. This will allow you to compare your current system against the proposed system once you have a scale model running.

It is imperative to find a partner that you can work well with. Several talks stressed the keys to a good partnership, and I have included some of them below:
  • It is important for companies to understand their process and share this with supply partners.
  • Choose a supplier you trust and can work with. They have to know what your concerns and goals are so they can build a system that works for you.
  • A supplier should have a quality package and service to help with validating the new system.
Supply partners can be a single vendor who will work to design a process using theirs and complimentary products. A company may also choose a supply partner that has the capability to utilize multiple product vendors to put together a system that is compatible.



Share this article with your social network, just click below to share now!


Monday, September 21, 2015

Closed Systems in Biomanufacturing Offer a Variety of Benefits


I recently attended IBC’s Biopharmaceutical Development and Production week (BDP) and was pleased to find talks focused on single-use technologies, flexible facilities, closed systems and continuous processing. These subjects are sometimes referred to as “biomanufacturing of the future,” because they represent a change in paradigm from traditional biomanufacturing. While we have covered single-use and continuous bioprocessing extensively on Cell Culture Dish in the past, we have not dedicated much time covering the benefits and opportunities associated with closed systems. This blog will attempt to provide a high-level review of some of the topics associated with closed systems and will provide several outside resources for readers who want to explore the topic in more detail.

Traditional Biopharmaceutical Manufacturing

Traditional biopharmaceutical manufacturing has mainly consisted of fed-batch stainless steel bioreactor runs in a fixed facility with an open system. This paradigm, while serving the biopharmaceutical industry well for many years, has faced increasing pressure as single product 20,000L scale manufacturing has begun to lose ground to smaller volume, multi-product manufacturing. This shift has occurred for several reasons, some include:

·         Increases in productivity have reduced the need for very large scale manufacturing vessels and dedicated facilities.
·         Fewer blockbuster drugs with high volumes have reduced the need for large-scale dedicated facilities.
·         Single-use technologies have enabled the implementation of smaller, more flexible manufacturing.
·         Companies have begun to embrace the idea of more flexible, multi-product facilities that can easily be scaled up or down to meet changing product demand.

As a result of the changing landscape, the traditional biomanufacturing paradigm has been challenged by new models including flexible facilities, single-use systems and continuous processes that can create a more flexible and in many cases more cost effective process. Biomanufacturing of the future incorporates technologies like single-use and models like closed systems and continuous processing to move the industry forward.

Closed and Functionally Closed Systems

There have been several definitions of what makes a closed or functionally closed system in biomanufacturing. All the definitions are similar, but I like the definitions used in the BioPharm International article “Challenging the Cleanroom Paradigm for Biopharmaceutical Manufacturing of Bulk Drug Substances.” The article provides the following definitions:
  • Closed system: A process system with equipment designed and operated such that the product is not exposed to the room environment. Materials may be introduced to a closed system, but the addition must be done in such a way to avoid exposure of the product to the room environment (e.g., by 0.2 μm filtration).
  • Functionally closed system: A process system that may be routinely opened (e.g., to install a filter or make a connection), but is returned to a closed state through a sanitization or sterilization step prior to process use. It is the owner’s responsibility to define and validate the sanitization or sterilization process required to return an opened system to a functionally closed system
Benefits of a Closed or Functionally Closed System

Reduced Risk of Contamination
One of the biggest and most easily attained benefits of implementing a closed system, whether in research, pilot or large scale, is in reducing the risk of contamination by viruses or other adventitious agents. Open systems naturally provide more opportunities for contamination because the process is open to the room environment and handling by operators. There are also safety concerns associated with breeches of product containment. Operations like fluid transfer present a much higher risk in an open system where splashing and lost media can occur. A closed system, by design, provides physical barriers to reduce the risk of contamination and contain the product.

This is important because contamination can be extremely costly, not only in product loss, but also facility shut downs, cleaning and validation.

Reduced Process Time
The use of a closed system can reduce operating time. A closed system relies on less operator handling and fewer overall steps. Another time saving factor is that many of the closed system components are plug and play meaning that they come pre-assembled, designed for the job they are intended. This reduces the time it takes to set up and launch a manufacturing system significantly.

If single use technologies are employed as part of the closed system, then more time savings can be achieved. Over the course of several talks, the use of single use technologies were reported to save anywhere from a couple of days to a couple of weeks. These times savings were reported in areas including:
  • Reduced cleaning and validation time
  • Reduced set-up time
  • Reduced time to operate or oversee equipment
Examples of Benefits
One example where there is a benefit to time savings and risk reduction is in media preparation. To enable a closed system, instead of mixing and adding media, one might purchase a pre-filled media bag with a connector that is complimentary to a single use bioreactor. This creates a closed portion of the process and saves operator time of mixing media. This method also reduces risk of contamination because the media isn’t exposed to the room environment and there is reduced risk of spilling and loss of media. Aseptic transfer of large volumes of sterile media and solution can be a big challenge.

Another example was provided in a talk at BDP, titled “Processes of the Future: Single Use, Closed and Continuous for Faster, Cheaper and Safer Manufacturing,” given by Sébastien Ribault, Ph.D., Director Biotechnology/Life Science, Head of BioDevelpment Center, EMD Millipore. BDP. In Dr. Ribault’s facility, his team is operating a closed system in one of their manufacturing areas. The group needed to close the cell seeding process, so instead of banking cells in vials, they banked the cells in bags. They then thawed the bags in a water bath and seeded directly in the lab without laminar flow. This saved them time and they reported similar growth and viability to the process using cells banked in vials.

Adopting a Risk Based Approach to Manufacturing Classifications
One hot topic in the discussion around closed systems is the idea of adopting a risk-based approach when it comes to the manufacturing classifications required with closed systems. If a system is closed, or functionally closed, then a barrier already exists between the product and its environment. Therefore, is there really a need for these operations to be conducted in a Classified environment with extensive gowning and airlocks, or would it be more feasible to conduct these operations in a Controlled Non-Classified (CNC) space? The benefits associated with this type of change in classification would provide many manufacturing benefits.

At BDP, Kenneth Green, Ph.D., Head of Manufacturing Science and Technology, Shire, gave an excellent talk titled, “Pushing the Controlled Non-Classified (CNC) Envelope with the Application of Single-Use Systems for Bioprocessing.” In the talk, Dr. Green discussed the debate around whether a closed system or functionally closed system could be proved to regulators, with satisfaction, so that manufacturing could occur in a controlled non-classified environment.

If so, operating in a Controlled Non Classified (CNC) space would open up many more benefits including:
  • Enabling a truly flexible facility – by reducing the classified area requirements you could also reduce the amount of segregation in a facility and increase flexibility. There are many benefits associated with flexible manufacturing, including:
    • Smaller facilities with a simpler design that can be duplicated in multiple locations
    • Multiple products can be manufactured in the same facility or space
    • Less segregation
    • Equipment can be moved around on skids as needed to meet product demand in multiple production lines.
    • Personnel can also move more easily throughout the facility
  • Reduced operating costs include:
    • Energy savings by reducing the environmental monitoring needed and the air handling requirements
    • Removing or reducing gowning requirements reduce cost of both gown materials and provide time savings for the gowning/de-gowning processes.
The idea of employing a risk-based approach in classification requirements is a very interesting topic that could be a blog entirely on its own; however for the purposes of this article, I am only providing a high level overview. There are a number of excellent articles that cover this topic in more detail including:



Challenges to Implementation of a Closed System

Employee Training
While most of these systems are fairly easy to use, there are some major differences between stainless steel systems and single-use. Employees should be trained in maintaining the closed or functionally closed system, proper use of equipment to prevent breakage or tears and employees need to be comfortable using the tubing and connectors.

Breaking New Ground
Completely closed systems represent relatively new technologies. Ensuring all parts of your system are closed may require a good deal of ingenuity and determination particularly when using components from several suppliers. There may not be an off the shelf component that works for you and you may need to work with suppliers to create systems that work for your process.

One example of this ingenuity and determination appeared in Dr. Veena Warikoo’s talk at BDP. Dr. Warikoo, Director, Purification Development, Genzyme, gave a talk titled “Integrated and Fully Continuous Processing of Recombinant Therapeutic Proteins – From Cell Culture Media to Purified Drug Substance.” In the talk she described how Genzyme developed a closed, continuous model system for manufacturing both mAbs and non-mAbs. They had been using a continuous system upstream but needed to also close the downstream process. There wasn’t an off the shelf solution available at the time, so they partnered with GE Healthcare to develop a functionally closed periodic counter-current chromatography continuous process. She showed a picture of the system they used, then stated that GE Healthcare now offers an off the shelf version in their AKTA system.

Demonstrating to Regulators that Systems are Closed and Adopting Risk Based Approach in Classification for Closed Systems
In order to fully gain all of the benefits mentioned above, the industry must work with regulators to demonstrate that CNC manufacturing space is appropriate. BioPhorum Operations Group (BPOG) is currently working to help interpret regulatory guidance and quality expectations and prepare responses that incorporate a risk based approach.

Is a closed system right for your process? – How to navigate a transition
I was able to speak with Erika Hanley-Onken and John Shyu at Corning Life Sciences about their experiences helping customers’ transition to closed systems. They said that they like to conduct a walk through with customers to understand on a technical level the customer’s current system and how that system will transition into a new closed system. They also work with multiple vendors to create a system designed to meet customer needs and goals. Lastly, they train the company on using the new system and they will work with customers to help validate the new system. When asked what customers are most surprised by when deciding to transition they said “how long it takes, it can take weeks to months to develop the system and test it, but we provide a full quality package and we want to ensure that the customer can achieve full and consistent results.”

Goals
First it is important to consider what is the primary goal in moving to a closed system. Some examples below:
  • Designing a new facility and want to incorporate flexible manufacturing principals
  • Quality control concerns and are interested in reducing risk of contamination
  • Process improvements with desire to reduce production time or cost
Design and Implementation of a Closed System
In determining the design and implementation of your closed system it is critical to truly understand your existing process needs, strengths and weaknesses. These factors can be very helpful when working with a vendor or vendors to establish your system. It is also important to understand your current cost of goods and net present value analysis, particularly if cost is a driving factor for change. This will allow you to compare your current system against the proposed system once you have a scale model running.

It is imperative to find a partner that you can work well with. Several talks stressed the keys to a good partnership, and I have included some of them below:
  • It is important for companies to understand their process and share this with supply partners.
  • Choose a supplier you trust and can work with. They have to know what your concerns and goals are so they can build a system that works for you.
  • A supplier should have a quality package and service to help with validating the new system.
Supply partners can be a single vendor who will work to design a process using theirs and complimentary products. A company may also choose a supply partner that has the capability to utilize multiple product vendors to put together a system that is compatible.
This blog was first published on CellCultureDish.com




Share this article with your social network, just click below to share now!


Monday, September 14, 2015

The 4Vs framework and its application in Biopharmaceutical manufacturing

Bioprocessing is an endeavor with some specific challenges associated with it, such as how we might implement single-use technologies or gain regulatory approval for new drugs. It seems to me, however, that it is easy to become so focused on topics such as these that we overlook applying established methods and practices used in a broad array of industries to improve our own. One such framework that could be applied to our sector is an analysis of the 4Vs of volume, variety, variation and visibility. Considering these parameters can help us make decisions about how to best organize biopharmaceutical manufacturing operations.

Volume: The number of doses of a biopharmaceutical to be manufactured varies considerably between drug products. Blockbuster products and products used to manage chronic diseases over long periods of time might be manufactured in large volumes. Due to the specific nature of biopharma drugs the patients that will respond to them can be small and the number of doses required not nearly so many. Orphan drugs for treating relatively rare diseases are a good example of products where the number of doses per year to be manufactured might be very low. Taking this to an extreme, personalized medicines and cell therapies are likely to be required is such small volumes that they are challenging existing industry processing technologies, supply networks and regulatory frameworks in order that they can be successfully commercialized.

Variety: Often linked by an inverse relationship to volume, variety refers to the number of different products an operation must deliver. In the above example of personalized medicine the variety of products to be produced may be very high as the products are in essence customized to the patient receiving them. Less variety tends to imply higher volume production and perhaps less operational complexity. Biopharmaceutical companies often strive to develop platform manufacturing processes capable of delivering a variety of products within their portfolio without adding to this complexity.

Variation: The degree to which demand for the product varies can have a significant impact on operation design. This variation can be more predictable, such as with the seasonal flu vaccines or less predictable, perhaps driven by competitor or regulatory activity. Responding to variations in demand can be a significant challenge for the biopharmaceutical industry where making process changes including process scale-up be a slow process with technical and regulatory challenges. Failure to design operations with sufficient agility to respond to demand fluctuations can result in increased lead times and patients not receiving medicines at the time they are required.

Visibility: Biomanufacturing operations are typically exposed to a high level of internal and external scrutiny due to the regulated nature of the industry. Process visibility is a term often used to describe operations that deliver services in which the customer is typically heavily involved in their design and operation. An example in biologics manufacturing are the use of Contract Manufacturing Organizations (CMOs). Once the decision has been made to outsource production, the management of the relationship between customer and contractor must be given significant attention to ensure successful delivery of drugs to patients and the sponsor must address issues such as relinquishing of some control.

Consideration of the 4Vs can help shape the design of biomanufacturing operations. For instance, high volume-low variety operations are typically more repetitive in nature and may suggest continuous biomanufacturing is an appropriate strategy. Companies requiring a small number of doses of a large number of products will need to design operations that permit a greater level of complexity and more intermittent processes. It is a framework worth reviewing when considering the future design of your companies bioprocessing footprint.




Join me at #BPIconf
Contact me at nick.hutchinson@parker.com

Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.



Share this article with your social network, just click below to share now!


Monday, July 27, 2015

How to successfully integrate continuous capture with perfusion bioreactors


In a previous post I described the drivers for, and, benefits from, the trend towards the continuousproduction of biopharmaceutical drugs in which I referenced the article of Veena Warikoo from Genzyme, a Sanofi company, and co-workers published in 2012 on the “Integrated Continuous Production of RecombinantTherapeutic Proteins” (Biotech Bioeng, 2012;109: 3018-3029). Amongst Veena’s contributing authors is Konstantin Konstantinov a key contributor to the literature on continuous bioprocessing and Keynote speaker at the Bioprocess International 2015 Conference with a presentation entitled “What is the Future of Continuous Processing  – What is the Time Frame for Implementing Fully Continuous Processing in Commercial Production?"
Extending continuous processing downstream to include the capture step

A key concept that the team from Genzyme developed is the integration of continuous chromatography with a perfusion bioreactor for the production of both high volume and stable monoclonal antibodies and low volume, less stable recombinant human enzymes. A 12 L bioreactor was operated for up to 70 days by utilizing the Alternating Tangential Flow (ATF) cell retention technology. The ATF permeate that was harvest was loaded directly onto a periodic counter current (PCC) chromatography system. Systems such as these are now available from a variety of suppliers including GE Healthcare, Pall, Semba and NovaSep. Genzyme were able to operate the PCC system in a fully closed and sterile state for a prolonged period of time.


The benefits of integrating continuous culture with continuous capture
Adopting this approach can lead to significant benefits because of the high cell densities and volumetric productivities that can be achieved. This allows significantly smaller bioreactors to be used thereby reducing facility size and capital costs. The ATF system eliminated the need for a more complex harvesting system, however, integration with PCC eliminated the need for large hold tanks, a non-value adding operation, and allowed the capture column to be reduced by a minimum of two-fold.

Improved product quality of less stable proteins

Integration of upstream and downstream operations in this way allows for the continuous flow of product from the bioreactor, through the capture step and into the chromatography eluate and mitigates the risk of product degradation of less stable proteins.

Though the issue of stability may be less of a concern for monoclonal antibodies, the team have created a platform capable of delivering a range of biopharmaceuticals from within a single facility.

What is the Time Frame for Implementing Fully Continuous Processing in Commercial Production?

How would you answer this question? Do you think the industry will see this within 5 years? 10 years? 20 years? Or more?

Dr Nick Hutchinson

Join me at #BPIconf

Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.


Share this article with your social network, just click below to share now!


Wednesday, April 8, 2015

BDP Week 2015: Conventional vs Single-Use Facilities Panel Discussion

By: Maribel Rios, Managing Editor of BioProcess International

On Wednesday, 1 April 2015, the Biopharmaceutical Development and Production Week meeting held a Q&A session between attendees and a selected panel, moderated by Adam Goldstein (Genentech, a member of the Roche group). Panelists included Nuno Fontes (Boehringer Ingelheim), David Fritsch (Fritsh Consulting), Francis Kobina Insaidoo, PhD (Merck Research Laboratories), Chris Antoniou (Biogen Idec), and James D. Vogel (The BioProcess Institute). The panel first discussed the merits of moving to an all-single-use facility, such as Amgen’s facility in Singapore as opposed to continuing to use a stainless-steel-based facility and making modifications with single-use systems. Questions and discussion focused on the following:

·         Does building a complete single-use facility make sense? The panel agreed that there are some processes (e.g., early stage, smaller volume, pilot studies) in which the complete or near-complete use of single-use systems make sense. Larger-volumen(>2,000 L), commercial-scale, and dedicated processes would be more susceptible for stainless-steel systems.
·         How does cost of goods and other economic factors play a role? The panel agreed that manufacturers must examine all factors carefully, including timelines for building a facility. Other concepts, such as ballroom-style or modular facilities also can reduce timelines.
·         Are there single-use solutions for high cell density and high-titer processes? And are there ideas for addressing the limitations of single-use mixing of such processes? The panel responded that work on “loop” systems is ongoing through companies such as HyClone/Thermo/GE.




Share this article with your social network, just click below to share now!


Tuesday, September 16, 2014

Alzheimer's Diagnosis and the Role of Biomarkers

Xuemei Zhao, Principal Scientist Merck Research Laboratories 

Alzheimers disease biomarkers marker identification diagnosisAlzheimer’s disease (AD) is the most common form of dementia and it is increasingly prevalent in people over 65 years old.  In developed countries, AD places a tremendous burden on individuals and society.  To date, the cause and progression of the disease are not fully understood.  Although symptomatic therapy has been approved, there is no agent available to stop or reverse the disease.  Many therapeutic candidates are in development with some showing promising results.  Clinical diagnosis of AD relies on characteristic neurological and neuropsychological features.  A definite diagnosis of AD, however, can only be made by examining the neuropathological hallmarks of the disease, amyloid plaques and neurofibrillary tangles, at autopsy.  Therefore, biomarkers that aid in the diagnosis of AD would have great value in the development of AD therapeutics and clinical practice. 

Protein markers in cerebrospinal fluid (CSF) and neuroimaging markers have been shown to contribute to the diagnosis of AD.  CSF protein biomarkers include total tau, phosphorylated tau, and the 42 amino acid form of amyloid-b (Ab42).  Some recently developed positron emission tomography (PET) agents for amyloid deposition imaging are the 11C Pittsburgh Compound B (11C-PIB) and newer, FDA-approved amyloid imaging agents such as Amyvid and Flutemetamol.  Other AD imaging modalities are atrophy on structural magnetic resonance imaging (MRI), and hypometabolism on [18F]fluorodeoxyglucose (FDG) PET.  The validity of these biomarkers of amyloid plaque deposition and neurodegeneration owing to AD is supported by autopsy correlation studies.  Implementation of these markers in the clinic, however, is not ideal in that CSF collection by lumbar puncture is a relatively invasive procedure and PET/MRI measurements are expensive, facility restricted, and may be further limited by personal conditions such as pacemakers.  Therefore, identification of robust biomarkers in an easily accessible body fluid would aid in the early detection of the disease and facilitate development of disease-modifying agents.  


We performed two independent studies, discovery and validation, to identify AD markers by profiling proteins in human plasma using the aptamer-based SOMAscanTM technology.  Specifically, we aimed to identify markers with better performance than the best-performing CSF markers, tau and Ab42, to discriminate AD from non-demented controls.  We constructed a 5-protein classifier in the discovery study and demonstrated that the plasma protein classifier allowed the prediction of AD with 100.0% sensitivity, 80.0% specificity, and 90.0% accuracy in an independent validation study, matching or outperforming CSF tau and Ab42.  Individual-matched plasma and CSF samples were obtained at the same visit, allowing direct comparison of diagnostic performance between the plasma protein classifier and CSF protein biomarkers.  Moreover, the classifier also correctly predicted mild cognitive impairment (MCI), an early pre-dementia state of the disease, with 96.7% sensitivity, 80.0% specificity, and 92.5% accuracy.  These studies demonstrate that plasma proteins could be used effectively and accurately to contribute to the clinical diagnosis of AD.  Although additional and more diverse cohorts are needed for further validation of the robustness, including the support of post mortem diagnosis, the 5-protein classifier appears to be a promising blood test to contribute diagnosis of AD. 

Learn more about Xuemei's work in identifying Alzheimer's disease. 

You can hear more from Xuemei at this year's Bioassay and Bioanalytical Method Development event.  Join us October 20-22 in Boston, MA.  Download the agenda here to see what else is on tap.   

SAVE $100. Register here and use code XP1969BLOG. 

Sign up for our e-mail updates
Follow us on Twitter
Join us on LinkedIn




Share this article with your social network, just click below to share now!